[Androgen may improve erectile function in castrated rats by regulating the ERK1/2 pathway]

Area of Science:

• Urology
• Endocrinology
• Molecular Biology

Background:

• Erectile dysfunction (ED) is often linked to testosterone deficiency.
• The extracellular signal-regulated protein kinase 1/2 (ERK1/2) pathway's role in testosterone-mediated erectile function requires further elucidation.

Purpose of the Study:

• To investigate the involvement of the ERK1/2 signaling pathway in testosterone-deficient erectile dysfunction.
• To assess the impact of androgen replacement on erectile function and related molecular markers.

Main Methods:

• Thirty male Sprague-Dawley rats were divided into control, castration, and castration + testosterone replacement groups.
• Serum testosterone levels, intracavernous pressure (ICP), and mean arterial pressure (MAP) were measured.
• Western blot analysis was used to determine the expression levels of ERK1/2 and endothelial nitric oxide synthase (eNOS).

Main Results:

• Castration significantly reduced serum testosterone, ICP, and MAP compared to controls.
• While ERK1/2 expression remained unchanged, its phosphatase activity was elevated, and eNOS expression was decreased in castrated rats.
• Testosterone replacement normalized testosterone levels, ICP, MAP, and reversed the changes in phosphatase ERK1/2 and eNOS expression.

Conclusions:

• Testosterone deficiency impairs erectile function, potentially through alterations in the ERK1/2 pathway and reduced eNOS expression.
• Androgen replacement therapy may improve erectile function in castrated rats by modulating the ERK1/2 pathway and restoring eNOS levels.